Please login to the form below

Not currently logged in
Email:
Password:

UCB launches epilepsy campaign

UCB has launched 'Epilepsy In Our Time' – a video campaign to mark the first European Epilepsy Day

UCB has launched 'Epilepsy In Our Time' – a video campaign to mark the first European Epilepsy Day.

The annual event is co-ordinated by the International Bureau for Epilepsy (IBE), an organisation comprising epilepsy associations from across the world, and the International League Against Epilepsy (ILAE), a global organisation representing healthcare professionals working in the field of epilepsy.

It is scheduled to be held each year on the second Monday in February, with plans to raise awareness of the condition across Europe.

UCB's campaign involves online video diaries made by people living with epilepsy. The company said the diaries provide an insight into modern perceptions of the condition, as well as what epilepsy is like to live with.

People involved in the series of videos include Marion, who won an Olympic silver medal in cycling for France in 2000, and Julie and David, whose 11-year-old son Dominic has severe epilepsy.

UCB has launched 'Epilepsy In Our Time'


Commenting on the 'Epilepsy In Our Time' campaign, Mike Glynn, president, IBE, said: "Epilepsy is the most common serious brain disorder, affecting 6 million people in Europe, but is an under-recognised and poorly understood condition, often leaving individuals exposed to stigma and prejudice. We welcome any new initiative that raises awareness and understanding of epilepsy."

European Epilepsy Day follows the annual Latin American Epilepsy Day held on September 9, with the IBE saying it plans to hold an annual day in each of its seven regions.

Plans for an international epilepsy day have been postponed until the World Health Organization is able to offer its support, according to the IBE.

Belgium-based biopharma UCB specialises in developing therapies for severe central nervous system or immunological disorders, and has several epilepsy drugs approved for marketing, including Vimpat (lacosamide) and Keppra (levetiracetam).

14th February 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics